Patterns of Response to Durvalumab Plus Tremelimumab and Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma
Anticancer Research · 2026
DOI: 10.21873/anticanres.18366 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2026. Verfasst von Akifumi Kuwano und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatology, Aso Iizuka Hospital, Iizuka, Japan; akuwanoh1@aih-net.com. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Antibodies, Monoclonal, Humanized, Antibodies, Monoclonal.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatology, Aso Iizuka Hospital, Iizuka, Japan; akuwanoh1@aih-net.com.
- Department of Hepatology, Aso Iizuka Hospital, Iizuka, Japan.
- Department of Gastroenterology, Ichinomiyanishi Hospital, Ichinomiya, Japan.
Zitieren
APA
Kuwano, A., Yada, M., Tanaka, K., Hamamoto, T., Tanaka, R., Kurosaka, K., Suzuki, H., & Motomura, K. (2026). Patterns of Response to Durvalumab Plus Tremelimumab and Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma. Anticancer Research. https://doi.org/10.21873/anticanres.18366
Vancouver
Kuwano A, Yada M, Tanaka K, Hamamoto T, Tanaka R, Kurosaka K, et al. Patterns of Response to Durvalumab Plus Tremelimumab and Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma. Anticancer Research. 2026. doi:10.21873/anticanres.18366
BibTeX
@article{Kuwano2026,
author = {Kuwano, Akifumi and Yada, Masayoshi and Tanaka, Kosuke and Hamamoto, Taikan and Tanaka, Ryotaro and Kurosaka, Kazuki and Suzuki, Hideo and Motomura, Kenta},
title = {Patterns of Response to Durvalumab Plus Tremelimumab and Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma},
journal = {Anticancer Research},
year = {2026},
doi = {10.21873/anticanres.18366}
}
EUVIMED